Literature DB >> 21718365

Transient blood eosinophilia during treatment with Adalimumab.

K Vester, R D Rüger, W Harth, J C Simon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21718365     DOI： 10.1111/j.1468-3083.2011.04169.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

Review 1.  Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence.

Authors:  Sambhawana Bhandari; Maun Ranjan Baral; Matthew Barbery; Alla Rudinskaya; Oleg Sostin
Journal:  Ann Hematol       Date:  2022-06-27       Impact factor: 4.030

2.  Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.

Authors:  Naoto Azuma; Kiyoshi Matsui; Naoaki Hashimoto; Takahiro Yoshikawa; Hajime Sano
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

3.  The relationship between blood eosinophil count and disease activity in ankylosing spondylitis patients treated with TNF-α inhibitors.

Authors:  Gokhan Sargin; Taskin Senturk; Irfan Yavasoglu
Journal:  Saudi Pharm J       Date:  2018-05-04       Impact factor: 4.330

4.  Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist.

Authors:  Sho Hayashida; Shunsuke Sato; Yuji Shimada; Hironori Tsuzura; Yuji Ikeda; Sho Takahashi; Sho Sato; Nozomi Amano; Ayato Murata; Akihito Nagahara; Takuya Genda
Journal:  Intern Med       Date:  2020-08-15       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.